Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab PRN regimen comparison in treatment-naive neovascular age-related macular degeneration
2012-003431-37Phase 4Active
- Sponsor
- Sociedad Española de Retina y Vítreo
- Start
- Oct 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in age-related macular degeneration (AMD) and Subretinal neovascularization (2 arms), sponsored by Sociedad Española de Retina y Vítreo. Primary endpoint: Mean change in best-corrected visual acuity. Started Oct 2012; status: active.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2012-003431-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003431-37.